Clinical trials testing cancer immunotherapies have significantly under-represented Black patients. So while these treatments have resulted in dramatically improved outcomes for some patients, researchers from the University of Michigan Rogel Cancer Center wanted to understand whether that success holds true for patients who are Black.
This article was originally published on MedicalXpress.com